Amendment: SEC Form SC 13G/A filed by Adicet Bio Inc.

$ACET
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $ACET alert in real time by email
SC 13G/A 1 acet1015245sc13ga2.htm AMENDMENT NO. 2

 

Securities and Exchange Commission

Washington, DC 20549

 

SCHEDULE 13G/A

 

 

Under the Securities Exchange Act of 1934

(Amendment No. 2)*

 

Adicet Bio, Inc.

(Name of Issuer)

 

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

 

 

 

007002108

(CUSIP Number)

 

 

 

September 30, 2024

(Date of Event Which Requires Filing of This Statement)

 

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

¨Rule 13d-1(b)

 

xRule 13d-1(c)

 

¨Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 Page 1 of 10 Pages 
  

 

CUSIP No. 007002108

 

13G/A Page 2 of 10 Pages

1

NameS of Reporting Persons
I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

 

Tang Capital Management, LLC

 

2 Check the Appropriate Box if a Member of a Group* (a)
(
b)
3

SEC Use Only

 

4

Citizenship or Place of Organization

 

DELAWARE

 

Number of
Shares
BENEFICIALLY
Owned by
Each Reporting
Person with
5

Sole Voting Power

 

6

Shared Voting Power

 

8,216,960

7

Sole Dispositive Power

 

8

Shared Dispositive Power

 

8,216,960

9

Aggregate Amount Beneficially Owned by each Reporting Person

 

8,216,960

10

Check Box if the Aggregate Amount in Row (9) excludes certain shares

 

¨

11

Percent of Class represented by amount in row 9

 

9.97% 

12

type of reporting person

 

OO

 

 Page 2 of 10 Pages 
  

 

CUSIP No.  007002108

 

13G/A Page 3 of 10 Pages
1

NameS of Reporting Persons
I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

 

Kevin Tang

 

2 Check the Appropriate Box if a Member of a Group* (a)
(
b)

3

SEC Use Only

 

4

Citizenship or Place of Organization

 

united states

 

Number of
Shares
BENEFICIALLY
Owned by
Each Reporting
Person with
5

Sole Voting Power

 

0 

6

Shared Voting Power

 

8,216,960

7

Sole Dispositive Power

 

0 

8

Shared Dispositive Power

 

8,216,960

9

Aggregate Amount Beneficially Owned by each Reporting Person

 

8,216,960

10

Check Box if the Aggregate Amount in Row (9) excludes certain shares

 

¨

11

Percent of Class represented by amount in row 9

 

9.97% 

12

type of reporting person

 

IN

 

 Page 3 of 10 Pages 
  

 

CUSIP No. 007002108

 

13G/A Page 4 of 10 Pages
1

NameS of Reporting Persons
I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

 

TANG CAPITAL PARTNERS, LP

 

2 Check the Appropriate Box if a Member of a Group* (a)
(
b)

3

SEC Use Only

 

4

Citizenship or Place of Organization

 

DELAWARE

 

Number of
Shares
BENEFICIALLY
Owned by
Each Reporting
Person with
5

Sole Voting Power

 

0 

6

Shared Voting Power

 

8,216,960

7

Sole Dispositive Power

 

8

Shared Dispositive Power

 

8,216,960

9

Aggregate Amount Beneficially Owned by each Reporting Person

 

8,216,960

10

Check Box if the Aggregate Amount in Row (9) excludes certain shares

 

¨

11

Percent of Class represented by amount in row 9

 

9.97% 

12

type of reporting person

 

pN

 

 Page 4 of 10 Pages 
  

 

CUSIP No. 007002108

 

13G/A Page 5 of 10 Pages
1

NameS of Reporting Persons
I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

 

TANG CAPITAL PARTNERS III, INC

 

2 Check the Appropriate Box if a Member of a Group* ( a)
(
b)

3

SEC Use Only

 

4

Citizenship or Place of Organization

 

NEVADA

 

Number of
Shares
BENEFICIALLY
Owned by
Each Reporting
Person with
5

Sole Voting Power

 

0

6

Shared Voting Power

 

0

7

Sole Dispositive Power

 

0

8

Shared Dispositive Power

 

0

9

Aggregate Amount Beneficially Owned by each Reporting Person

 

0

10

Check Box if the Aggregate Amount in Row (9) excludes certain shares

 

¨

11

Percent of Class represented by amount in row 9

 

0%

12

type of reporting person

 

CO

 

 Page 5 of 10 Pages 
  

 

CUSIP No. 007002108

 

13G/A Page 6 of 10 Pages
1

NameS of Reporting Persons
I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

 

TANG CAPITAL PARTNERS IV, INC

 

2 Check the Appropriate Box if a Member of a Group* ( a)
(
b)

3

SEC Use Only

 

4

Citizenship or Place of Organization

 

NEVADA

 

Number of
Shares
BENEFICIALLY
Owned by
Each Reporting
Person with
5

Sole Voting Power

 

0

6

Shared Voting Power

 

0

7

Sole Dispositive Power

 

0

8

Shared Dispositive Power

 

0

9

Aggregate Amount Beneficially Owned by each Reporting Person

 

0

10

Check Box if the Aggregate Amount in Row (9) excludes certain shares

 

¨

11

Percent of Class represented by amount in row 9

 

0%

12

type of reporting person

 

CO

 

 Page 6 of 10 Pages 
  

 

Item 1(a).Name of Issuer:

 

Adicet Bio, Inc., a Delaware corporation (the “Issuer”)

 

Item 1(b).Address of Issuer’s Principal Executive Offices:

 

131 Dartmouth Street, Floor 3, Boston, MA 02116

 

Item 2(a).Name of Person Filing:

 

This Statement on Schedule 13G (this “Statement”) is filed by Tang Capital Management, LLC, the general partner of Tang Capital Partners, LP (“Tang Capital Management”); Kevin Tang, the manager of Tang Capital Management and the Chief Executive Officer of Tang Capital Partners III, Inc. and Tang Capital Partners IV, Inc.; Tang Capital Partners, LP (“Tang Capital Partners”); Tang Capital Partners III, Inc. (“Tang Capital Partners III”); and Tang Capital Partners IV, Inc. (“Tang Capital Partners IV”).

 

Item 2(b).Address of Principal Business Office or, if none, Residence:

 

The address of Tang Capital Management, Kevin Tang and Tang Capital Partners is 4747 Executive Drive, Suite 210, San Diego, CA 92121. The address of Tang Capital Partners III and Tang Capital Partners IV is 5955 Edmond Street, Las Vegas, NV 89118.

 

Item 2(c).Citizenship:

 

Tang Capital Management is a Delaware limited liability company. Mr. Tang is a United States citizen. Tang Capital Partners is a Delaware limited partnership. Tang Capital Partners III and Tang Capital Partners IV are Nevada corporations which are indirectly wholly owned by Tang Capital Partners.

 

Item 2(d).Title of Class of Securities:

 

Common Stock, par value $0.0001 per share (the “Common Stock”)

 

Item 2(e).CUSIP Number: 007002108

 

Item 3.Not applicable.

 

Item 4.Ownership.

 

(a)Amount Beneficially Owned:

 

Tang Capital Management. Tang Capital Management beneficially owns 8,216,960 shares of the Issuer’s Common Stock.

 

Tang Capital Management shares voting and dispositive power over such shares with Tang Capital Partners and Kevin Tang.

 

Kevin Tang. Kevin Tang beneficially owns 8,216,960 shares of the Issuer’s Common Stock.

 

Kevin Tang shares voting and dispositive power over such shares with Tang Capital Partners and Tang Capital Management.

 

 Page 7 of 10 Pages 
  

 

Tang Capital Partners. Tang Capital Partners beneficially owns 8,216,960 shares of the Issuer’s Common Stock.

 

Tang Capital Partners shares voting and dispositive power over such shares with Tang Capital Management and Kevin Tang.

 

The percentages used herein are based on 82,400,960 shares of Common Stock outstanding as of August 9, 2024, as set forth in the Issuer’s Quarterly Report filed on Form 10-Q that was filed with the Securities and Exchange Commission on August 13, 2024.

 

(b)Percent of Class:

 

Tang Capital Management 9.97%
Kevin Tang 9.97%
Tang Capital Partners 9.97%
Tang Capital Partners III 0.00%
Tang Capital Partners IV 0.00%

 

(c)Number of shares as to which such person has:

 

(i)      sole power to vote or to direct the vote:

 

Tang Capital Management 0 shares
Kevin Tang 0 shares
Tang Capital Partners 0 shares
Tang Capital Partners III 0 shares
Tang Capital Partners IV 0 shares

 

(ii)    shared power to vote or to direct the vote:

 

Tang Capital Management 8,216,960 shares
Kevin Tang 8,216,960 shares
Tang Capital Partners 8,216,960 shares
Tang Capital Partners III 0 shares
Tang Capital Partners IV 0 shares

 

(iii)    sole power to dispose or to direct the disposition of:

 

Tang Capital Management 0 shares
Kevin Tang 0 shares
Tang Capital Partners 0 shares
Tang Capital Partners III 0 shares
Tang Capital Partners IV 0 shares

 

(iv)   shared power to dispose or to direct the disposition of:

 

Tang Capital Management 8,216,960 shares
Kevin Tang 8,216,960 shares
Tang Capital Partners 8,216,960 shares
Tang Capital Partners III 0 shares
Tang Capital Partners IV 0 shares

 

Item 5.Ownership of Five Percent or Less of a Class.

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: o

 

 Page 8 of 10 Pages 
  

 

Item 6.Ownership of More than Five Percent on Behalf of Another Person.

 

Not applicable

 

Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

 

Not applicable.

 

Item 8.Identification and Classification of Members of the Group.

 

Not applicable.

 

Item 9.Notice of Dissolution of Group.

 

Not applicable.

 

Item 10.Certification.

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

 Page 9 of 10 Pages 
  

 

Signature

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

 

Date:  

November 14, 2024

 
     
     
TANG CAPITAL PARTNERS, LP  
     
By:   Tang Capital Management, LLC, its General Partner  
     
     
By:   /s/ Kevin Tang  
   Kevin Tang, Manager  
     

TANG CAPITAL PARTNERS III, INC

     
     
By: /s/ Kevin Tang  
Kevin Tang, Chief Executive Officer  
     

TANG CAPITAL PARTNERS IV, INC

 
     
     
By:   /s/ Kevin Tang  
  

Kevin Tang, Chief Executive Officer

 
     

TANG CAPITAL MANAGEMENT, LLC

     
     
By: /s/ Kevin Tang  

Kevin Tang, Manager

 
     

     
/s/ Kevin Tang  
Kevin Tang  

 

 

Page 10 of 10 Pages

 

 

 

Get the next $ACET alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ACET

DatePrice TargetRatingAnalyst
9/30/2024$7.00Buy
Guggenheim
9/11/2024Buy → Neutral
H.C. Wainwright
6/27/2023Buy → Neutral
Guggenheim
6/27/2023Mkt Outperform → Mkt Perform
JMP Securities
6/1/2023$20.00 → $6.00Overweight → Neutral
JP Morgan
9/21/2022$23.00Overweight
JP Morgan
3/31/2022$28.00Outperform
SMBC Nikko
3/8/2022$30.00Buy
Truist Securities
More analyst ratings

$ACET
Press Releases

Fastest customizable press release news feed in the world

See more
  • Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress

    Phase 1 clinical trial of ADI-001 in autoimmune diseases ongoing; on track to report preliminary clinical data from lupus nephritis (LN) patient cohort in 1H25 Additional LN clinical data and preliminary clinical data from other autoimmune patient cohorts anticipated in 2H25 Initiation of ADI-001 Phase 1 clinical trial patient enrollment in systemic lupus erythematosus (SLE), systemic sclerosis (SSc), idiopathic inflammatory myopathy (IIM) and stiff person syndrome (SPS) expected in 2Q25; anti-neutrophil cytoplasmic autoantibody (ANCA) associated vasculitis (AAV) patient enrollment expected to be initiated in 2H25 Advancing patient enrollment in ADI-270 Phase 1 clinical trial in patients

    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting

    Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the acceptance of two abstracts for poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting taking place March 12-14, 2025, in San Diego, C.A. Details of the poster presentation are as follows: Abstract Title: ADI-270, an Armored Allogeneic Anti-CD70 γδ CAR T Cell Therapy, Demonstrates Improved Efficacy and Safety in Preclinical Models Compared to Conventional αβ CAR Benchmarks Poster/Abstract Number: 39 Presenting Author: Shon Green, Ph.D. Date/

    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc)

    Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ADI-001 for the potential treatment of adult patients with systemic sclerosis (SSc). Fast Track Designation is a process designed to facilitate development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need. About ADI-001 ADI-001 is an investigational allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapy targeting CD20 for the treatment of autoimmune di

    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ACET
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ACET
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$ACET
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ACET
SEC Filings

See more

$ACET
Leadership Updates

Live Leadership Updates

See more
  • Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer

    Dr. Maltzman Brings Oncology and Autoimmune Experience in All Stages of Drug Development, from Early-Stage Research to Successful Regulatory Approvals and Commercialization Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the appointment of Julie Maltzman, M.D. as Chief Medical Officer, effective January 13, 2025. Dr. Maltzman will lead the Adicet clinical development strategy to advance Adicet's robust autoimmune and oncology pipeline. "We are incredibly pleased to welcome Julie to the Adicet team. Her vast experience in successfully leading the c

    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Adicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors

    Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the appointment of Lloyd Klickstein, M.D., Ph.D. to its Board of Directors. "We are pleased to welcome Dr. Klickstein to our Board of Directors," said Chen Schor, President and Chief Executive Officer of Adicet Bio. "Dr. Klickstein's expertise in rheumatology and immunology, proven track record in drug development and his scientific knowledge of our gamma delta T cell platform as a former executive at Adicet will be very valuable as we progress our autoimmune programs across multiple indications. I loo

    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Adicet Reports Second Quarter 2023 Financial Results and Provides Business Updates

    Announced encouraging safety and efficacy data in ongoing Phase 1 study of ADI-001 for the potential treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) On track to report a clinical update for ADI-001 in second half of 2024 Plan to file Investigational New Drug Application (IND) for ADI-925 in H2 2023 and ADI-270 in H1 2024 Strong balance sheet with $205.5 million in cash and cash equivalents as of June 30, 2023 Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights for the second quarter ended June 30, 2023.

    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ACET
Financials

Live finance-specific insights

See more
  • Adicet Provides Corporate Update and Highlights Strategic Priorities for 2024

    Expanding clinical development of ADI-001 into autoimmune diseases following clearance of Investigational New Drug Application (IND); plan to initiate Phase 1 clinical study in 2Q 2024 Focusing enrollment on mantle cell lymphoma (MCL) in ongoing ADI-001 Phase 1 clinical trial given favorable complete response (CR) rate, durability, and safety ADI-001 clinical update expected 2H 2024 ADI-270 IND submission in renal cell carcinoma expected in 2Q 2024 Updated cash runway into 2H 2025 Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and autoimmune diseases, today provided corporate upda

    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Adicet Bio to Host Conference Call to Provide Updates on its Clinical Pipeline and Corporate Outlook

    Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that the Company will host a conference call and webcast presentation on Thursday, January 4, 2024 at 8:00am ET to provide an update on its clinical pipeline and corporate outlook. Conference Call and Webcast Event The live webcast of the presentation can be accessed by registering under "Presentations & Events" in the investors section of the Company's website at https://www.adicetbio.com. Upon registration, all participants will receive a confirmation email with a unique passcode to provide access to the webcast event. To

    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)

    ADI-001 demonstrated 71% overall response rate (ORR) and 63% complete response (CR) rate across all dose levels in patients with median 4 prior lines of therapy; 50% of patients enrolled had previously progressed on anti-CD19 chimeric antigen receptor T cell (CAR T) therapy 83% ORR and 67% CR rate observed in heavily pre-treated patients who had progressed on prior CAR T Six-month CR rate consistent with autologous CAR T cell therapy Favorable safety with no significant incidence of CRS (cytokine release syndrome) or ICANS (immune effector cell associated neurotoxicity syndrome) Robust pharmacokinetic profile in dose level 4 (DL4) with Cmax and Day 28 persistence exceeding approved

    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ACET
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more